Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002970 · ClinicalTrials.gov registry record · Phase 2
506U78 in Treating Patients With Refractory Hematologic Cancer
A Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 148
- Enrollment target
- 1
- Study location
NCT00002970 is a Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 148 participants, above the 114-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (30% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00002970, a Phase 2 study of Recurrent Childhood Acute Lymphoblastic Leukemia and Recurrent Childhood Lymphoblastic Lymphoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
Conditions Studied
Interventions
- DRUG methotrexate
- DRUG cytarabine
- DRUG therapeutic hydrocortisone
- DRUG nelarabine
Study Locations (1)
California
- Children's Oncology Group - Arcadia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 1997-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002970
The ClinicalTrials.gov registry entry for NCT00002970 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 114-participant average among 11 other Recurrent Childhood Acute Lymphoblastic Leukemia trials with a reported enrollment target (30% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Recurrent Childhood Acute Lymphoblastic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which methotrexate is the first listed.
NCT00002970 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00002970 about?
NCT00002970 is a clinical study titled "506U78 in Treating Patients With Refractory Hematologic Cancer". Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
What is the current status of trial NCT00002970?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 148 participants. The study started on 1997-06.
What conditions does trial NCT00002970 study?
This clinical trial studies the following conditions: Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia.
What interventions are being tested in trial NCT00002970?
The interventions under investigation include: methotrexate (DRUG), cytarabine (DRUG), therapeutic hydrocortisone (DRUG), nelarabine (DRUG).
Who is sponsoring clinical trial NCT00002970?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002970 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Acute Lymphoblastic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML
ACTIVE NOT RECRUITING · Phase 2
-
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
RECRUITING · Phase 1
-
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RECRUITING · Phase 1
-
Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
DNA Analysis of Tumor Tissue Samples From Young Patients With Acute Lymphoblastic Leukemia
COMPLETED
-
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
COMPLETED · Phase 1
Explore more on PlainTrial
Recurrent Childhood Acute Lymphoblastic Leukemia
All registered trials for this condition
Recurrent Childhood Lymphoblastic Lymphoma
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.